Complete Omics Inc. Proudly Welcomes Proteomics Luminary Dr. Hui Zhang as Chief Scientific Officer

January 12, 2024 | BALTIMORE –  Complete Omics’ Clinical Proteomics team are thrilled to announce that Dr. Hui Zhang, a distinguished figure in the realm of proteomics, has joined the Complete Omics family as our Chief Scientific Officer (CSO) and Director for the Center for Advanced Proteomics. Dr. Zhang, a founding member of the Clinical Proteomic Tumor Analysis Consortium (CPTAC), brings to our team a rich legacy of innovation and leadership in proteomics, especially known for her pioneering work in multi-omics studies on human cancers and her revolutionary innovation on the methods in studying N-Glycosylation on proteins.

Read more >
Read more

Securing a Brighter Future: Celebrating Our Investment from Qiming Venture Partners

November 25, 2023 | BALTIMORE –  Complete Omics management team are thrilled to announce a significant milestone for our company – a recent investment by Qiming Venture Partners. This partnership marks a pivotal moment in our journey, as we continue to advance our clinical proteomics platform and molecular diagnostics platform development. With this investment, we are poised to accelerate our efforts in bringing innovative solutions to the healthcare industry, ultimately aiming to improve patient outcomes through cutting-edge diagnostics.

Read more >
Read more

Complete Omics Inc. Founder Qing Wang Featured on Wharton Business School’s Official Website

July 27, 2023 | BALTIMORE –  Complete Omics is proud to announce a momentous occasion for Complete Omics Inc.: our visionary founder, Qing Wang, has been featured on the prestigious Wharton Business School’s official website in a piece that celebrates and explores the journey of empowering entrepreneurs.

Read more >
Read more

Thrilled to Welcome Dr. Raghothama Chaerkady as the Leader of Our Clinical Proteomics Team

July 15, 2023 | BALTIMORE –  Complete Omics team are excited to announce that Dr. Raghothama Chaerkady, a globally recognized proteomics expert, has joined us as the leader of our clinical proteomics team, MyProt Force. Dr. Chaerkady’s journey in proteomics is marked by his instrumental role in publishing the milestone paper, “A Draft Map of the Human Proteome,” in Nature in 2014—a work that has significantly advanced the field of proteomics, particularly in biomarker discovery.

Read more >
Read more

Exciting News from the MyMeta Force Team!

June 1, 2023 | BALTIMORE –  Complete Omics’ Clinical Metablomics team are overjoyed to announce that Dr. Liang Zhao, an esteemed expert in metabolomics, proteomics, and lipidomics, with a profound focus on cancer metabolism and immuno-metabolism, has joined our MyMeta Force team as the leader. Dr. Zhao’s pioneering research involves the sophisticated application of mass spectrometry-based metabolomics and proteomics, alongside integrating molecular biology and bioinformatics, to unravel the biomedical significance of metabolites and proteins. His dedication to translating omics findings into clinical applications is notable, aiming at the development of innovative biomarkers, AI-enhanced diagnostic panels, and novel therapeutic strategies for cancer treatment.

Read more >
Read more

Exciting Feature: Complete Omics and Our Founder Qing Wang Shine on The Scientist’s Channel!

July 18, 2021 | BALTIMORE –  Complete Omics team is thrilled to announce an extraordinary milestone for Complete Omics Inc. The Scientist’s Channel, renowned for spotlighting the trailblazers at the forefront of scientific inquiry and innovation, has featured our esteemed founder, Qing Wang, in a compelling showcase that highlights the groundbreaking work we are doing here at Complete Omics.

Read more >
Read more

Collaboration with Columbia University

Mar 30, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Kam W. Leong, Samuel Y. Sheng professor of Biomedical Engineering, and his team from Columbia University on a clinical proteomics project focusing on leveraging our Complete360 quantitative proteomics assays for clinical discoveries.

Read more

Collaboration with Tel Aviv University

Mar 20, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Miguel Weil from Department of Cell Research and Immunology at the Tel Aviv University on a clinical proteomics project focusing on leveraging our Complete360 body fluid proteomics assays for clinical discoveries.

Read more

Detecting and Absolutely Quantifying Patient-specific Neoantigens from Limited Input of Biopsy Sample — An Integrated Pipeline for Neoantigen-targeted Cancer Treatments

Feb 28, 2022 | BALTIMORE –  Complete Omics Inc, a multi-omics molecular diagnostics company, today announces the publication of a new peer reviewed paper in the academic journal CANCERS, presenting a new pipeline developed for validating and absolutely quantifying neoantigens from very limited amount of clinical samples.

Read more >
Read more

Collaboration with Lisbon School of Medicine

Feb 26, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Dr. Luis Marques da Costa and his team from Lisbon School of Medicine on a clinical proteomics project focusing on leveraging our Complete360 body fluid proteomics assays for clinical discoveries.

Read more
Follow by Email
Facebook
Twitter
LinkedIn